Earnings call transcript: BIO-key Q2 2025 reports revenue surge, stock dips

BIO-key International Inc. (BKYI) reported a significant increase in revenue for the second quarter of 2025, with a 49% rise compared to the same period last year. Despite these positive financial results, the company’s stock fell 2.24% to $0.794 in premarket trading, reflecting investor concerns over broader market conditions and future guidance. According to InvestingPro analysis, the stock appears undervalued compared to its Fair Value, though it has seen a significant 36.35% decline over the past six months.

Key Takeaways

• Q2 2025 revenue increased by 49% year-over-year to $1.7 million.
• Gross profit rose by 40%, but gross margin slightly decreased to 73%.
• The net loss improved significantly from $1.7 million to $1.2 million.
• Stock price dropped 2.24% in premarket trading following the earnings report.

Company Performance

BIO-key demonstrated strong performance in Q2 2025, with revenue climbing to $1.7 million, a 49% increase from $1.1 million in Q2 2024. This growth was driven by advancements in their biometric identity and access management solutions, as well as strategic initiatives in the defense and intelligence sectors. The company maintains impressive gross profit margins of 80.03% over the last twelve months, though Q2’s slight decrease to 73% indicates some pricing pressures. InvestingPro data reveals 11 additional key insights about BKYI’s financial health and market position, available to subscribers.

Financial Highlights

• Revenue: $1.7 million, up 49% from $1.1 million in Q2 2024.
• Gross profit: $1.2 million, up 40% from $900,000.
• Net loss: $1.2 million ($0.20 per share), improved from $1.7 million ($1.00 per share).
• Current assets: $4 million, with $2.3 million in cash.
• Accounts receivable: Increased 37% to $984,000.

Outlook & Guidance

BIO-key anticipates continued growth in the cybersecurity sector, particularly in Europe, driven by increased defense spending and investments. The company projects EPS losses of $0.13 and $0.08 for the next two quarters, with revenue forecasts of $1.8 million and $2.19 million, respectively. Long-term, they expect annual revenues to reach $9 million by 2026. InvestingPro’s comprehensive analysis indicates the company’s financial health score is "FAIR," with particularly strong metrics in growth potential and relative value, though profitability remains a challenge.

Executive Commentary

CEO Mike DePasquale emphasized the strategic importance of EU and Middle East markets, stating, "These spending initiatives... are multiyear investments that are going to go on for five plus years." He also highlighted the company’s unique position in the market: "Customers want one throat to choke. They want to be able to buy everything from us and know that we’re there to support everything."

Risks and Challenges

• Decreasing gross margins could indicate rising costs or pricing pressure.
• Dependence on defense and intelligence contracts, which may be subject to geopolitical risks.
• Potential cash flow constraints if projected revenues do not materialize as expected.
• The competitive landscape in biometric and cybersecurity solutions remains intense.

BIO-key’s strategic focus on defense and cybersecurity sectors, combined with its innovative product offerings, positions it well for future growth. However, the market’s cautious response to its guidance reflects concerns over execution risks and broader market conditions.

Full transcript - BIO-Key International Inc (BKYI) Q2 2025:

Conference Operator: Good morning, everyone. Thank you for standing by, and welcome to BIO key International’s Second Quarter twenty twenty five Earnings Call. During management’s prepared remarks, all participants will be in a listen only mode. Afterwards, listeners will be invited to participate in a question and answer session. As a reminder, this conference is being recorded today, Wednesday, 08/13/2025.

I will now turn the call over to Bill Jones, Investor Relations. You may proceed.

Bill Jones, Investor Relations, BIO-key International: Thank you, Betsy. Hosting today are BIO key’s Chairman and CEO, Mike DePasquale and its CFO, Cece Welch. As a reminder, today’s call and webcast as well as answers to investor questions include forward looking statements, which are subject to risks and uncertainties that may cause actual results to differ materially from current expectations. Words like anticipate, believe, expect, plan and project or any similar words identify and express forward looking statements. These statements are made based on the beliefs, assumptions and information currently available to management as of today and are pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

For a more complete description of the risks and uncertainties that may affect future performance, please see Risk Factors in the company’s annual report on Form 10 ks as filed with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on forward looking statements made as of today, and the company makes no obligation to revise or disclose revisions to such statements to reflect circumstances or events that may occur after this call. Now, I will turn the call over to Mike to begin. Mike?

Mike DePasquale, Chairman and CEO, BIO-key International: Thanks, Bill, and thank you all for joining us today. After my brief remarks and Cece’s financial review, we will open the call to investor questions. BIO key had a solid Q2 performance with revenue rising 49% versus last year and 6% on a sequential basis. We also advanced our expense reduction initiatives, trimming SG and A expenses by 13.5% versus last year, more than offsetting increased investments in R and D to further enhance the capabilities of our solutions. We’ve also reduced our note payable to a balance of $447,000 from $1,000,000 at the December 2024.

Turning to business highlights in the quarter, BIO key and our partner run level secured a major identity and access management deployment with the National Bank of Mozambique. Also in Q2, we extended our penetration of the defense intelligence market based on the capabilities and strength of our IAM and in particular, our biometric enabled solutions. We are highly limited in what we can say about security and defense customer engagements. But what I can say is that we completed the first phase of a deployment for a new international defense agency customer and a respected Middle East police force commenced a three year PortalGuard deployment. In addition, we secured $600,000 of follow on orders for prominent foreign defense ministry that bring this ongoing project to over $3,000,000 in total revenue over the last few years.

Building on our success with a growing list of foreign military and defense customers, today we announced the formation of the BIO key cyber defense initiatives. We plan to staff this effort with sales and support executives that have strong military and intelligence experience to guide our efforts and to expand our market reach by building engagement with leading defense industry contractors. The initial focus of the cyber defense initiatives will be in the EU, in Europe, where we have key reference accounts and member countries have committed to substantially expanding military and defense investments. Europe’s Readiness ’2 30 framework and ReARM Europe plans aim to mobilize over €800,000,000,000 in defense investment over the next four years. Included within these efforts is the Security Action for Europe or SAFE loan mechanism, raising €150,000,000,000 for defense readiness, including missile defense drones and of course cybersecurity.

Similarly, NATO members recently agreed to increase their defense and security spending to at least 5% of their GDP by 02/1935, more than doubling the previous long standing target of 2% of GDP. Of the new 5% spending target, 1.5% is explicitly allocated to cybersecurity and security related investments, including strengthening network defenses against cyber attacks. The EU complements these efforts through initiatives to secure five gs networks and critical infrastructures, as well as a dedicated action plan for cybersecurity in vital services like hospitals and healthcare providers. This unprecedented increase in spending is deemed essential for deterring aggression and countering complex hybrid threats. Outside the defense sector, we are particularly encouraged about overall growth opportunities in the EMEA regions of Europe, The Middle East and Africa, where we have been seeing improved traction and a particular interest in our differentiated identity bound biometric capabilities.

We’ve refocused our efforts on BIO key branded solutions in those markets following our transition away from the former licensed Swivel Secure solutions and services that we were selling in 2024 and previous to that. Though it takes time to rebuild the opportunity pipeline and and channel strategy to focus solely on the BIO key product suite, we are seeing good traction and positive year over year revenue comparisons as we progress through the year. From a margin perspective, our focus on BIO key solutions provides us greater control and stronger gross margins, supporting our expectations for growth and enhanced margins from the EMEA group in the 2025. Finally, across the business, we have been developing a new marketing program to better articulate our unique capabilities and compelling value proposition. Given the complexity and competition that exists in our space, we realized it was time to bring a new voice and focus to our core value proposition to better support our channel partners and direct sales efforts.

In North America, we continue to build on our strong position in higher ed, healthcare and other public sector segments as well as finance and insurance. Benefiting from our growing base of reference accounts and IT professionals who have experienced firsthand the competitive strengths and value that we provide, in particular with our biometrics. In addition, we are taking steps to revitalize our North American direct and channel sales efforts by recruiting new leadership and cultivating a more collaborative and competitive sales culture to drive improved results. We are also moving back to an in office model for our sales, business development and marketing teams once again, which is identical to the way we operated before the COVID pandemic. In closing, we believe these strategic business development initiatives, coupled with our growing base of global channel partners, customers and reference accounts, put BIO key in a strong position to deliver improved top and bottom line results in 2025 and beyond.

We also continue to seek opportunities to reduce costs across the business to lower our breakeven level and support our path to positive cash flow and profitability. I’m excited about our potential over the coming quarters and appreciate the patience and support of our investors who have helped us get to this place. Now I will pass the call to Cece Welch to review BIO key financials.

Cece Welch, CFO, BIO-key International: Thank you, Mike. Our results were released this morning via press release, and I will now talk about some of the highlights. Our Q2 twenty twenty five revenue increased 49% to $1,700,000 versus $1,100,000 in Q2 twenty twenty four with improvements in each segment. The most significant contributor was 458,000 increase in hardware revenue, principally due to additional deployments of finger biometric scanners for a large long time customer. License fee revenue increased 4% in Q2 twenty twenty five, reflecting our growing base of Saracen sorry, subscription contracts, our service revenue increased 11% largely to the benefit of customer service for a large customer upgrade.

Q2 twenty twenty five gross profit increased by $354,000 or 40% to $1,200,000 from $900,000 in Q2 twenty twenty four due to the increase in total revenue offset by a modest decline in gross margin to 73% in Q2 twenty twenty five versus 77% in Q2 twenty twenty four. The year over year margin decrease was the result of a large increase in hardware revenue as a percentage of sales in the current year period as it carries a lower margin than license fees and services. BIO key reduced operating expenses by approximately $217,000 or 8.5% to $2,300,000 in Q2 twenty twenty five versus $2,500,000 in Q2 twenty twenty four due to a 13.5% reduction in SG and A expenses, resulting from reductions in administrative, sales personnel costs and professional service fees. As Mike mentioned, the SG and A improvement was partially offset by higher research and development costs in support of development of next generation products, such as our portal guard upgrade and the exploration of new products and new product line. Reflecting higher revenues and lower operating costs, ISK’s Q2 twenty twenty five net loss improved to $1,200,000 or zero two zero dollars per share from a net loss of $1,700,000 or $1 per share in Q2 twenty twenty four.

Our per share amounts are based on 5,800,000.0 weighted average shares outstanding in Q2 twenty twenty five compared to $1,700,000 in Q2 twenty twenty four, principally related to the share issuances from the warrant exercise and other financing related activity. As of 06/30/2025, BIO key had current assets of $4,000,000 including $2,300,000 in cash, up from the current from the year end current assets of $1,900,000 which included $438,000 of cash. Accounts receivable also increased 37% to $984,000 in June 2025 from $718,000 at year end in 2024. And now operator, at this time, please prepare for Q and A session.

Conference Operator: We will now begin the question The first question today comes from Dan Thomas with who is a private investor. Please go ahead.

Dan Thomas, Private Investor: Hi, guys. With the increased costs for this, I guess, sales and support team on the cyber defense and increased R and D, should we expect the recent trend towards reduced operating expenses to reverse?

Mike DePasquale, Chairman and CEO, BIO-key International: No. Well, again, I want to answer that question the right way, Dan. By the way, good morning. So no, the answer to that question is we had a I’ll call it a blip in the second quarter due to a few things. Number one, some restructuring in sales.

I mentioned in my prepared remarks, we were doing some changes in leadership and sales and business development resourcing. So that’s number one. Number two, events and that’s just the timing. We attend a couple of core events each year. One of them is Gartner, one is Identiverse, ISC squared, attend that event as well.

And so the timing of and the payment, right, for those events is one element. And I think we believe that the expense run rate that we started the year at from will pretty much be the way we proceed through the third and fourth quarter. So again, it was about a $300,000 blip in Q2.

Dan Thomas, Private Investor: Okay. Can you give us any at all additional color on what meaningful contract activity in the first half of next year means? Cybersecurity in Europe, I think?

Mike DePasquale, Chairman and CEO, BIO-key International: Yes, it’s pretty significant. I think our challenge, in fact, we have contracts that we’ve closed already this quarter and late last quarter and this quarter that we really just can’t discuss. It’s a very robust market, in particular for us for our very specific solutions. We provide not only an MFA, but an identity and access management platform with PortalGuard. And we’re pretty much the only vendor that has a solid proven biometric attachment to ratchet up the level of security for access management for these defense contractors and ultimately the end use defense agencies.

And so because of our powerful references, that business is going to grow for us. And so we announced the formal initiative. I mean, we’ve been working this for the past year, but we announced the formal initiative this morning to go after that business in a bigger way, and we’ll be doing some marketing and some other things to ensure that all of the contractors and the end use agencies know about BIO key, because many of these large contracts are hosted and managed by large primes, right? And on an international basis, we know who all of them are. We have very good partner relationships already in EMEA.

And this is just making it more significant for us. It’s no secret, right, that The U. S. Has forced the EU and the Middle East to step up and spend more to defend themselves and to also acquire product, missiles, weapons, all kinds of drones and other technology from The U. S.

As well. So there’s no doubt that the money is there. There’s no doubt that the need is there. And with our references, in particular with some very high level agencies that we haven’t even discussed or announced and we can’t yet, We think we’re in a really good position to capture that. And that’s again on the government side, but we also have a very robust enterprise business.

I mean, look at our business in banking and in healthcare. In education, we have well over 100 customers that represent millions and millions of users every day that use our technology. I don’t want anyone to think that we’re moving away in any way shape or form from the enterprise business, but I think what we’re trying to say here is we’re going to take advantage of the thermals that exist now because of this increase in the defense and intelligence markets that’s recently evolved.

Dan Thomas, Private Investor: Okay. When you say you have contracts that you can’t mention or I’m just wondering, have you received the income from those contracts already in the second quarter? Or are those contracts scheduled to come in the first half of next year or something? I’m just trying to get a feel for how

Mike DePasquale, Chairman and CEO, BIO-key International: No, both. Both. Was very clear. I mentioned we have already contracts that we’ve again closed at the end of last quarter this quarter in Q3, And they’ll be reflected in the Q3 results, right? I mean, again, can’t really announce the names or any of that at this point.

At some point, perhaps we will be able to do that. But at this point, we can’t. And so I think even in Q2, the certainly, at least I look at the stock price, and I don’t think it’s reflective of our performance today. And I think that the market just yet at this point doesn’t realize, again, our opportunity. And unfortunately, it’s going to happen.

It’s going to be shown in the results because a lot of the things that we are involved in right now are just not announceable. It’s just the way it is. And I don’t think we’re the only company in this position, but certainly for us right now, that’s our situation.

Dan Thomas, Private Investor: Okay. But you’re saying that these things you haven’t announced that they’ll be providing income in the next year and that’s some of what you’re basing this idea of meaningful contract activity? Or are you just expecting that because of the increased market in Europe and in EMEA? That’s what I’m

Mike DePasquale, Chairman and CEO, BIO-key International: trying say. No, no, no. This is a pipe dream. There will be results this quarter from some of these contracts in Q3. This is Q3.

We’re in Q3 and Q4 and obviously beyond. But these are real contracts that have generated revenue already and will continue to generate revenue through the end of this year and into next year and beyond, right? Obviously, these are this spending initiatives that are in particular in The EU and in The Middle East are multiyear, right? These are not just onetime kind of blips. These are investments that are going to go on for five plus years, maybe even longer.

Dan Thomas, Private Investor: Okay. Do you expect these to ramp, I guess? I guess, I’m trying to understand, I mean we’ve lost $1,000,000 I think in this quarter. So these have to ramp for you to get to breakeven. So are you expecting like a growth significant growth from these in the first half?

Is that what’s going on?

Mike DePasquale, Chairman and CEO, BIO-key International: Oh, absolutely. There’s no question. I mean, again, it’s iterative, right? These things will grow. The quantity of opportunities customers will grow as will the size.

And typically, these things start and then they iterate. If you look at that, first, our largest defense ministry, right, we’ve iterated to multimillion dollar to multiple millions of dollars in sales, both hardware and software with them over the last few years. And so these are the things that continue, right? They start and then they iterate. They get bigger.

More users get added. More touch points get added, I. E. That represents hardware. But one other point that I want to make, our blended gross margins still are 70 plus percent, which is very, very strong.

They float right between 7080%. But at the end of the day, those are very, very strong and powerful gross margins. And I think a testament to the quality and the nature of our solution set. Customers want one throat to choke. They want to be able to buy everything from us and know that we’re there to support everything.

So again, that’s also very powerful for us.

Dan Thomas, Private Investor: Okay. You mentioned some of this has happened in the third quarter. I think last call you mentioned that during the summer, I guess Europe shuts down in August and whatnot. Do we have a feel at all for whether we’ll get growth in the third quarter or whether we might see a little bit of a slowdown before a ramp back up in the fourth quarter, anything like that?

Mike DePasquale, Chairman and CEO, BIO-key International: Yes. Well, we don’t provide guidance, so I’m not going there. But there’s no question that Europe right now, right, we’re in dead portion of the summer in Europe, and that will continue through the end of the month. But in September, things will wake back up again. So we’re encouraged by our pipeline and the number of opportunities we have.

And in the context of also on this kind of defense intelligence segment, it’s typically a priority. So it’s less impacted by the, I’ll call it, the malaise that you see typically in the European summer because these things are mission critical, right? So they may obviously have less staff or a diminished focus, but the focus doesn’t go away as it will sometimes you’ll see that in the enterprise or commercial markets in Europe. But you’ll see less of that in the defense and intelligence sectors.

Dan Thomas, Private Investor: Okay. That’s helpful. How much of the reserve inventory did you sell? Can you give us that?

Mike DePasquale, Chairman and CEO, BIO-key International: Yes. We’re selling it basically every quarter. We sold a bunch already this quarter in Q3. We continue to move that inventory and our goal and objective is to again by the end of the year to move the bulk of it. So I keep mentioning, and I’ve mentioned this on a number of calls, that we have a few larger opportunities to move higher volumes of those units, and that’s starting to come to pass for us.

So you’ll see that reflected in the numbers as we evolve forward. And of course, as you know, they’ve all been written down, so it’s revenue and it’s also all cash. So it’s good for us and all margin.

Dan Thomas, Private Investor: Right. Right. But can you tell us how much you have left?

Mike DePasquale, Chairman and CEO, BIO-key International: No.

Dan Thomas, Private Investor: Do these hardware sales lead or lag software sales? Noticed a big increase.

Mike DePasquale, Chairman and CEO, BIO-key International: They usually come together. So typically the initial contract or sale will include software and the hardware to get the solution up going, users registered, deployed, and then the expansion will typically include software and maybe some hardware. So there might be less, there might be more. In the context of our large Defense Ministry customer, they’ve deployed, I believe, 40,000 touch points, meaning they’ve deployed 40,000 finger scanners in different locations throughout their infrastructure. And they continue now to add users, right?

More and more larger portions of their population are now getting enrolled because they have a wide distribution of touch points and they fundamentally have mandated that anyone who accesses anything that has to do with their intelligence infrastructure must utilize the BIO key solution. And every one of those touch points has a BIO key logo on it, just FYI.

Dan Thomas, Private Investor: Can you give us any update on Nigeria or Africa? That’s still

Mike DePasquale, Chairman and CEO, BIO-key International: We still operate there and we really have turned our focus to supporting our core products right now. We have a number of partners that we’ve signed up through our EMEA group Africa that will be representing us, but more for our core technology and core products. The volatility on the other side of the market, I call it the civil ID market, it’s just not worth our effort at this point. We do believe though in Africa as an emerging market, but more on the as you see, we closed two deals in two banking deals in Africa in the first half, right? The Bank of Mozambique and Egypt.

We have another one in the pipeline that we hope will close this quarter or next. So going after the commercial enterprise market, in particular with our biometric solutions, it seems like a very powerful opportunity. So that’s our focus right now in Greater Africa. I see.

Dan Thomas, Private Investor: Last question. You think you have enough cash and equivalents to get you through the end of the year?

Mike DePasquale, Chairman and CEO, BIO-key International: Yes, we do.

Dan Thomas, Private Investor: Okay. I’ll get back in the queue. Thank you for the time.

Mike DePasquale, Chairman and CEO, BIO-key International: Thanks,

Conference Operator: There are no further questions at this time. I’d like to turn the call back over for any closing remarks.

Mike DePasquale, Chairman and CEO, BIO-key International: Thank you everyone for taking the time with us today. You may reach out to our IR team whose contact information is in today’s press release with any follow-up questions. Also, we expect participate in a number of conferences as we evolve forward through the end of the year and stay tuned for those announcements. We certainly will keep you posted. With that, have a great day, a great rest of the week and a great rest of the summer.

We look forward to updating you on our call after in the late fall, in the mid fall in October. Have a great day.

Conference Operator: Conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.